PriceTargets.com logo

IMV - IMV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 05/10/2023 09:00 PM ET
+0 (0.00%)
Get New IMV Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMV

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for IMV in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for IMV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in IMV. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/2/2023HC WainwrightDowngradeBuy ➝ Neutral
3/16/2023HC WainwrightLower TargetBuy$65.00 ➝ $19.00
2/13/2023HC WainwrightReiterated RatingBuy$65.00
12/21/2022HC WainwrightBoost TargetBuy$13.00 ➝ $65.00
5/13/2022Echelon Wealth PartnersReiterated RatingBuy
3/18/2022Raymond JamesLower TargetMarket Perform$17.50 ➝ $15.00
2/25/2022Raymond JamesSet TargetMarket Perform$17.50
12/22/2021Raymond JamesSet TargetMarket Perform$17.50
11/12/2021Raymond JamesLower TargetMarket Perform$20.00 ➝ $17.50
9/22/2021Cantor FitzgeraldInitiated CoverageOverweight$40.00
8/11/2021National Bank FinancialReiterated RatingSector Perform Market Weight
7/23/2021Wells Fargo & CompanyInitiated CoverageOverweight$13.80
7/16/2021Raymond JamesLower TargetMarket Perform$30.00 ➝ $20.00
5/13/2021Raymond JamesSet TargetMarket Perform$30.00
3/18/2021Leede Jones GabReiterated RatingSpeculative Buy
3/18/2021National BanksharesLower TargetSector Perform$70.00 ➝ $52.50
3/18/2021Raymond JamesReiterated RatingMarket Perform$30.00
12/29/2020Raymond JamesSet TargetMarket Perform$30.00
12/4/2020Raymond JamesSet TargetMarket Perform$30.00
11/11/2020Raymond JamesSet TargetMarket Perform$30.00
11/5/2020Raymond JamesSet TargetMarket Perform$30.00
10/9/2020Raymond JamesSet TargetMarket Perform$30.00
8/12/2020HC WainwrightReiterated RatingBuy$130.00
8/7/2020National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market Weight
8/6/2020Raymond JamesSet TargetMarket Perform$30.00
7/22/2020HC WainwrightReiterated RatingBuy$130.00
7/21/2020Industrial Alliance SecuritiesInitiated CoverageBuy$100.00
7/15/2020Raymond JamesSet TargetMarket Perform$30.00
7/14/2020Wells Fargo & CompanyBoost Target$85.00 ➝ $110.00
6/1/2020Raymond JamesSet TargetMarket Perform$30.00
6/1/2020HC WainwrightReiterated RatingBuy$130.00
5/25/2020Echelon Wealth PartnersReiterated RatingBuy$90.00
5/19/2020Raymond JamesSet TargetMarket Perform$30.00
5/18/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$25.00 ➝ $85.00
5/15/2020HC WainwrightBoost TargetBuy$115.00 ➝ $130.00
3/31/2020HC WainwrightReiterated RatingBuy$115.00
3/31/2020B. RileyDowngradeBuy ➝ Neutral$70.00 ➝ $30.00
3/31/2020Raymond JamesSet TargetMarket Perform$30.00
3/18/2020HC WainwrightReiterated RatingBuy$115.00
3/18/2020Raymond JamesDowngradeOutperform ➝ Market Perform$45.00 ➝ $30.00
2/27/2020Echelon Wealth PartnersReiterated RatingBuy$90.00
2/26/2020Raymond JamesLower TargetOutperform$100.00 ➝ $45.00
2/25/2020HC WainwrightReiterated RatingBuy$115.00
2/25/2020B. RileyReiterated RatingBuy$110.00
2/25/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$35.00
2/10/2020HC WainwrightReiterated RatingBuy$115.00
2/6/2020B. RileyReiterated RatingBuy$110.00
1/28/2020BTIG ResearchInitiated CoverageBuy$80.00
1/21/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$30.00 ➝ $60.00
(Data available from 1/7/2020 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/11/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/10/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/9/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/9/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/7/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
IMV logo
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.66
Low: $0.49
High: $0.91

52 Week Range

Now: N/A

Volume

44,800 shs

Average Volume

233,607 shs

Market Capitalization

$9.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of IMV?

The following Wall Street sell-side analysts have issued research reports on IMV in the last twelve months:
View the latest analyst ratings for IMV.

What is the current price target for IMV?

0 Wall Street analysts have set twelve-month price targets for IMV in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IMV in the next year.
View the latest price targets for IMV.

What is the current consensus analyst rating for IMV?

IMV currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMV.

What other companies compete with IMV?

Other companies that are similar to IMV include Lexaria Bioscience, Lumos Pharma, Akari Therapeutics, Hillstream BioPharma and ProMIS Neurosciences. Learn More about companies similar to IMV.

How do I contact IMV's investor relations team?

IMV's physical mailing address is 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4. The company's listed phone number is (902) 492-1819 and its investor relations email address is [email protected]. The official website for IMV is imv-inc.com. Learn More about contacing IMV investor relations.